Edition:
United States

Profile: Valeant Pharmaceuticals International Inc (VRX.TO)

VRX.TO on Toronto Stock Exchange

15.49CAD
1:52pm EDT
Change (% chg)

$-0.06 (-0.39%)
Prev Close
$15.55
Open
$15.60
Day's High
$15.67
Day's Low
$15.25
Volume
619,866
Avg. Vol
1,363,791
52-wk High
$32.50
52-wk Low
$11.20

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Company Address

Valeant Pharmaceuticals International Inc

2150 Saint-Elzear Blvd W
LAVAL   QC   H7L 4A8
P: +1514.7446792
F: +1514.7446272

Company Web Links